Tremelimumab: tested in a combination
143 studies: another drug in the study is under test too. Page 2 of 2. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerActive, not recruitingNCT03682068Phase 3Report a problem
- Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCCCompletedNCT03624231Phase 2Report a problem
- Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell CanerTerminatedNCT03618134Phase 1/2Report a problem
- Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder CancerActive, not recruitingNCT03601455Phase 2Report a problem
- NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial CarcinomaActive, not recruitingNCT03549715Phase 1/2Report a problem
- Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid TumoursCompletedNCT03518606Phase 1/2Report a problem
- Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompletedNCT03509012Phase 1Report a problem
- Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA PatientsCompletedNCT03473574Phase 2Report a problem
- Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast CancerTerminatedNCT03430466Phase 2Report a problem
- Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCCActive, not recruitingNCT03410615Phase 2Report a problem
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingNCT03385655Phase 2Report a problem
- Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT03317457Phase 2Report a problem
- Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT03317158Phase 1/2Report a problem
- Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedNCT03292250Phase 2Report a problem
- Immunotherapy With Neo-adjuvant Chemotherapy for OVarian CancerCompletedNCT03249142Phase 1/2Report a problem
- Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell CancerCompletedNCT03144778Phase 1Report a problem
- Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLCWithdrawnNCT03130764Phase 2Report a problem
- Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid CancerCompletedNCT03122496Phase 1Report a problem
- Durvalumab Alone or With Tremelimumab in Refractory Germ Cell TumorsTerminatedNCT03081923Phase 2Report a problem
- Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract CancerActive, not recruitingNCT03046862Phase 2Report a problem
- Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureCompletedNCT02997995Phase 2Report a problem
- A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced MalignanciesCompletedNCT02978482Phase 1Report a problem
- Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerActive, not recruitingNCT02962063Phase 1/2Report a problem
- Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid TumorsTerminatedNCT02938793Phase 2Report a problem
- Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic CancerWithdrawnNCT02868632Phase 1Report a problem
- MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2Report a problem
- Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryActive, not recruitingNCT02812420Early Phase 1Report a problem
- Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell CarcinomaCompletedNCT02762006Phase 1Report a problem
- Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1Report a problem
- Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1Report a problem
- A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)Status unknownNCT02588131Phase 2Report a problem
- MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedNCT02549651Phase 1Report a problem
- Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy RegimensActive, not recruitingNCT02537418Phase 1Report a problem
- A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerCompletedNCT02262741Phase 1Report a problem
- A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid TumorsCompletedNCT02261220Phase 1Report a problem
- Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ MesotheliomaCompletedNCT02141347Phase 1Report a problem
- Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic SyndromeCompletedNCT02117219Phase 1Report a problem
- Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC PatientsCompletedNCT02040064Phase 1Report a problem
- A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02000947Phase 1Report a problem
- A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursCompletedNCT01938612Phase 1Report a problem
- Tremelimumab and CP-870,893 in Patients With Metastatic MelanomaCompletedNCT01103635Phase 1Report a problem
- A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic CancerCompletedNCT00556023Phase 1Report a problem
- CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate CancerCompletedNCT00075192Phase 1/2Report a problem